Effectiveness of mRNA boosters against symptomatic infection and severe COVID-19 in Brazil and Scotland
January 2022: International collaboration study looking at the effectiveness of COVID-19 mRNA booster vaccines after Pfizer BioNTech (BNT162b2) or Oxford-AstraZeneca (ChadOx1) primary vaccines in preventing symptomatic infection and severe COVID-19.
Effectiveness of mRNA boosters after homologous primary series with BNT162b2 or ChAdOx1 against symptomatic infection and severe COVID-19 in Brazil and Scotland: A test-negative design case–control study
Cerqueira-Silva, T; Shah, S.A; Robertson, C; Sanchez, M; et. al.
Published on: 11 January 2023
Available online at: https://doi.org/10.1371/journal.pmed.1004156